NCT03219255 - RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term) | Biotech Hunter

Enrollment

1,047

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

March 30, 2021

Study Completion Date

March 30, 2021

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

RELVAR 100 ELLIPTA

RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.

Trial Locations (2)

003-0825

GSK Investigational Site, Hokkaido

211-0025

GSK Investigational Site, Kanagawa